TW375612B - 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same - Google Patents
1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the sameInfo
- Publication number
- TW375612B TW375612B TW085103445A TW85103445A TW375612B TW 375612 B TW375612 B TW 375612B TW 085103445 A TW085103445 A TW 085103445A TW 85103445 A TW85103445 A TW 85103445A TW 375612 B TW375612 B TW 375612B
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- formula
- hydrogen
- piperidinyl
- imidazol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical class O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 title 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000003197 catalytic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002255 enzymatic effect Effects 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- -1 bicyclo[2.2.1]-2-heptenyl Chemical group 0.000 abstract 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95200870 | 1995-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW375612B true TW375612B (en) | 1999-12-01 |
Family
ID=8220175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW085103445A TW375612B (en) | 1995-04-06 | 1996-03-22 | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5869515A (zh) |
| EP (1) | EP0832071B1 (zh) |
| JP (1) | JP4115519B2 (zh) |
| KR (1) | KR100400159B1 (zh) |
| CN (1) | CN1103760C (zh) |
| AR (1) | AR002984A1 (zh) |
| AT (1) | ATE305455T1 (zh) |
| CA (1) | CA2216542C (zh) |
| DE (1) | DE69635224T2 (zh) |
| ES (1) | ES2250988T3 (zh) |
| IL (1) | IL117806A (zh) |
| MY (1) | MY117936A (zh) |
| TW (1) | TW375612B (zh) |
| WO (1) | WO1996031487A1 (zh) |
| ZA (1) | ZA962753B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922751A (en) * | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
| ES2196308T3 (es) * | 1996-10-02 | 2003-12-16 | Janssen Pharmaceutica Nv | Derivado de 2-cianoiminoimidazol que inhiben la pde iv. |
| AU760771B2 (en) | 1998-04-01 | 2003-05-22 | Janssen Pharmaceutica N.V. | PDE IV inhibiting pyridine derivatives |
| SK287231B6 (sk) | 1999-08-21 | 2010-04-07 | Nycomed Gmbh | Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora |
| US20030175314A1 (en) * | 2001-11-19 | 2003-09-18 | Didriksen Erik Johannes | Pharmaceutical composition for dermal application |
| AU2004226353A1 (en) | 2003-04-01 | 2004-10-14 | Laboratoires Serono Sa | Inhibitors of phosphodiesterases in infertility |
| FR2860514A1 (fr) * | 2003-10-03 | 2005-04-08 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| GEP20084550B (en) | 2004-04-30 | 2008-11-25 | Warner Lambert Co | Substituted morpholine compounds for the treatment of central nervous system disorders |
| WO2006078698A1 (en) * | 2005-01-19 | 2006-07-27 | Cengent Therapeutics, Inc. | 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases |
| EP1987009A1 (en) * | 2006-01-30 | 2008-11-05 | Euro-Celtique S.A. | Cyclourea compounds as calcium channel blockers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4636516A (en) * | 1981-02-19 | 1987-01-13 | Yamanouchi Pharmaceutical Co., Ltd. | 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds |
| CA1309096C (en) * | 1985-08-13 | 1992-10-20 | Sumitomo Chemical Co., Ltd. | Butenoic acid derivatives, and their production and use |
| US4845233A (en) * | 1987-09-11 | 1989-07-04 | Iprx, Inc. | Imidazolin-2-ones |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| IL106517A0 (en) * | 1992-07-28 | 1994-08-26 | Rhone Poulenc Rorer Ltd | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group |
| EP0711282B1 (en) * | 1993-07-28 | 2002-06-05 | Aventis Pharma Limited | Compounds as pde iv and tnf inhibitors |
| GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
| GB9412672D0 (en) * | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| WO1996000218A1 (en) * | 1994-06-24 | 1996-01-04 | Euro-Celtique, S.A. | Compounds for and method of inhibiting phosphodiesterase iv |
-
1996
- 1996-03-22 TW TW085103445A patent/TW375612B/zh not_active IP Right Cessation
- 1996-03-28 EP EP96911969A patent/EP0832071B1/en not_active Expired - Lifetime
- 1996-03-28 ES ES96911969T patent/ES2250988T3/es not_active Expired - Lifetime
- 1996-03-28 JP JP52995896A patent/JP4115519B2/ja not_active Expired - Lifetime
- 1996-03-28 CA CA002216542A patent/CA2216542C/en not_active Expired - Lifetime
- 1996-03-28 US US08/930,478 patent/US5869515A/en not_active Expired - Lifetime
- 1996-03-28 KR KR1019970706852A patent/KR100400159B1/ko not_active Expired - Lifetime
- 1996-03-28 DE DE69635224T patent/DE69635224T2/de not_active Expired - Lifetime
- 1996-03-28 WO PCT/EP1996/001393 patent/WO1996031487A1/en not_active Ceased
- 1996-03-28 AT AT96911969T patent/ATE305455T1/de active
- 1996-03-28 CN CN96193104A patent/CN1103760C/zh not_active Expired - Lifetime
- 1996-04-03 IL IL11780696A patent/IL117806A/xx not_active IP Right Cessation
- 1996-04-03 AR ARP960102075A patent/AR002984A1/es active IP Right Grant
- 1996-04-04 ZA ZA9602753A patent/ZA962753B/xx unknown
- 1996-04-05 MY MYPI96001299A patent/MY117936A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4115519B2 (ja) | 2008-07-09 |
| MY117936A (en) | 2004-08-30 |
| IL117806A (en) | 2000-02-17 |
| AU697390B2 (en) | 1998-10-01 |
| AR002984A1 (es) | 1998-05-27 |
| CN1103760C (zh) | 2003-03-26 |
| KR19980703448A (ko) | 1998-11-05 |
| KR100400159B1 (ko) | 2003-12-31 |
| DE69635224T2 (de) | 2006-06-22 |
| EP0832071B1 (en) | 2005-09-28 |
| DE69635224D1 (de) | 2006-02-09 |
| ES2250988T3 (es) | 2006-04-16 |
| CA2216542A1 (en) | 1996-10-10 |
| JPH11504003A (ja) | 1999-04-06 |
| WO1996031487A1 (en) | 1996-10-10 |
| ATE305455T1 (de) | 2005-10-15 |
| US5869515A (en) | 1999-02-09 |
| ZA962753B (en) | 1997-10-06 |
| IL117806A0 (en) | 1996-08-04 |
| EP0832071A1 (en) | 1998-04-01 |
| CA2216542C (en) | 2009-01-13 |
| AU5497996A (en) | 1996-10-23 |
| CN1181073A (zh) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9707652A (es) | Derivados de 1,3-dihidro-1-(fenilalquil)-2h-imidazol-2-ona y composiciones que los contienen usados com inhibidores de fosfodiesterasa iv y de citocina, y procedimiento para preparar dichos derivados. | |
| MY116980A (en) | Pde iv inhibiting 2-cyanoiminoimidazole derivatives | |
| HUT70426A (en) | Pyrazolo-pyrimidine derivatives, process for preparing them and pharmaceutical compositions containing them as active agents | |
| HUT46313A (en) | Process for producing 3/2h/-pyridazine derivatives and pharmaceutical compositions containing them as active components | |
| TW375612B (en) | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same | |
| CA2216546A1 (en) | 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2-one derivatives having pde iv and cytokine inhibiting activity | |
| MY124696A (en) | Pde iv inhibiting pyridine derivatives. | |
| AU560420B2 (en) | Phenoxymethyl pyridine derivatives | |
| AU703163B2 (en) | Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions | |
| NO176608C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater | |
| US20040002509A1 (en) | Novel substituted imidazole compounds | |
| DE3370625D1 (en) | Benzhydrylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |